Assays in Focus
Developing Antibody Drug Conjugate (ADC) therapeutics? Inotiv has mass spectrometry assays to quantify your ADC target protein in any sample type, including FFPE tissue, without antibodies. We have developed assays to 27 ADC targets for oncology and other therapeutic applications.
Neuroscience
Revolutionize Drug Discovery with Inotiv’s Comprehensive Neuroscience Program
In vivo solutions for Developmental and Reproductive Toxicology and Juvenile Animal Studies
Count on our expertise in IBD animal models for your next in vivo study
Discover our array of highly characterized PDX models
Expect More From Your Discovery, Development and Research Models Partner
General Toxicology
General Toxicology
Inotiv offers a range of general toxicology studies to evaluate the safety of drugs, medical devices, and other chemicals. We design and conduct studies according to international regulations and our toxicology expertise can help assess potential risks and ensure the safety of your product.
Histology
Histology
Our industry-leading histology laboratories support your discovery and nonclinical development projects with a wide range of services. From tissue processing to digital analysis, our team delivers the quality you expect.
Pathology
Pathology
Access our world-class anatomical, clinical, and medical device pathology team that provides services from histochemistry to digital pathology including IHC, IF, and ISH to stereology, and more.
DMPK
DMPK
From hit-to-lead to lead optimization through candidate selection, our in vitro, in vivo, and bioanalytical teams offer the fit-for-purpose solutions you need at any stage of development to help you analyze, answer, and advance.
Consulting
Consulting
Our experts deliver the insights you deserve to get the answers you need, whether in DMPK data analysis, biomarker analysis, or bioequivalence studies.
Research Models
Research Models
Paired with the most comprehensive range of research models in the industry, we offer the experience, animal welfare, quality, and consistency that is essential to your success.
Research Model Services
Research Model Services
Our research model services group provides high-quality support services worldwide, including genetically engineered models and services (GEMS), contract breeding services, surgical services, and more.
Teklad Diet and Bedding
Teklad Diet and Bedding
What comes out of your research depends in large part on what goes into your research models. Ensuring models have the most appropriate laboratory animal diet, bedding, and enrichment is critical to maintaining consistent, reliable data.
Explore Our Full Offering of Services and Products
Discovery and Development
Inotiv delivers a broad array of nonclinical and analytical services from discovery through clinical development.
Research Models and Services
Inotiv provides the broadest range of research models and related services to pharmaceutical and biotech companies, government, academia, and other life science organizations.
The Latest From Inotiv
On-demand Webinar
Not All IBD Models Are Created Equally
How Differences Between Experimental IBD Models Can Impact Your Drug Development Program
Scientific Poster
Comparative Evaluation of Different Plating Methodologies and Sources of Induced S9 Metabolic Activation on the Mutagenic Potential of N-Nitrosodipropylamine Using the Ames Test
Due to the current FDA concern and guidance on reducing the risk of Nitrosamine impurities in human drugs, there has been an increased industry need for testing of these impurities using the Bacterial Reverse Mutation (Ames) test. As Nitrosamines are not readily detectable by standard Ames methodologies, specifically cited in the Ames testing guideline (OECD 471), the need for a robust protocol better suited for this class of compounds is warranted.
Society of Toxicologic Pathology (STP)
June 22-25, 2025 Chicago, IL Booth #101 We’re excited to participate in the STP’s 44th Annual Meeting, centered on the theme: “Toxi...
British Society of Toxicological Pathology (BSTP)
July 1-3, 2025 | July 8-10, 2025 8:00 AM – 2:00 PM ET Online live sessions We’re excited to announce our participation in the BSTP's
Characterizing Lipid Nanoparticles for RNA Therapeutic Development Webinar with DDN
July 17, 2025 11:00 AM – 12:30 PM ET Online webinar The therapeutic promise of RNA depends on effective delivery, with lipid nanoparticles (LNPs) serving as the most widely used ve...
Tapping Into the Full Therapeutic Potential of GLP-1
Dale Wright and Brian Bond from Inotiv discuss the importance of taking a holistic approach to glucagon-like peptide-1 re...
Inotiv Reports Second Quarter Financial Results for Fiscal 2025 and Provides Business Update
May 7, 2025 — Second quarter fiscal 2025 revenue increased 4.4% to $124.3 million — Year-to-date fiscal 2025 revenue de...
Inotiv, Inc. to Report Fiscal 2025 Second Quarter Financial Results and Host Conference Call on Wednesday, May 7, 2025
April 23, 2025 WEST LAFAYETTE, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”...
On-demand Webinar
Not All IBD Models Are Created Equally
How Differences Between Experimental IBD Models Can Impact Your Drug Development Program
Scientific Poster
Comparative Evaluation of Different Plating Methodologies and Sources of Induced S9 Metabolic Activation on the Mutagenic Potential of N-Nitrosodipropylamine Using the Ames Test
Due to the current FDA concern and guidance on reducing the risk of Nitrosamine impurities in human drugs, there has been an increased industry need for testing of these impurities using the Bacterial Reverse Mutation (Ames) test. As Nitrosamines are not readily detectable by standard Ames methodologies, specifically cited in the Ames testing guideline (OECD 471), the need for a robust protocol better suited for this class of compounds is warranted.
Society of Toxicologic Pathology (STP)
June 22-25, 2025 Chicago, IL Booth #101 We’re excited to participate in the STP’s 44th Annual Meeting, centered on the theme: “Toxi...
British Society of Toxicological Pathology (BSTP)
July 1-3, 2025 | July 8-10, 2025 8:00 AM – 2:00 PM ET Online live sessions We’re excited to announce our participation in the BSTP's
Characterizing Lipid Nanoparticles for RNA Therapeutic Development Webinar with DDN
July 17, 2025 11:00 AM – 12:30 PM ET Online webinar The therapeutic promise of RNA depends on effective delivery, with lipid nanoparticles (LNPs) serving as the most widely used ve...
Tapping Into the Full Therapeutic Potential of GLP-1
Dale Wright and Brian Bond from Inotiv discuss the importance of taking a holistic approach to glucagon-like peptide-1 re...
Inotiv Reports Second Quarter Financial Results for Fiscal 2025 and Provides Business Update
May 7, 2025 — Second quarter fiscal 2025 revenue increased 4.4% to $124.3 million — Year-to-date fiscal 2025 revenue de...
Inotiv, Inc. to Report Fiscal 2025 Second Quarter Financial Results and Host Conference Call on Wednesday, May 7, 2025
April 23, 2025 WEST LAFAYETTE, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”...
On-demand Webinar
Not All IBD Models Are Created Equally
How Differences Between Experimental IBD Models Can Impact Your Drug Development Program
Scientific Poster
Comparative Evaluation of Different Plating Methodologies and Sources of Induced S9 Metabolic Activation on the Mutagenic Potential of N-Nitrosodipropylamine Using the Ames Test
Due to the current FDA concern and guidance on reducing the risk of Nitrosamine impurities in human drugs, there has been an increased industry need for testing of these impurities using the Bacterial Reverse Mutation (Ames) test. As Nitrosamines are not readily detectable by standard Ames methodologies, specifically cited in the Ames testing guideline (OECD 471), the need for a robust protocol better suited for this class of compounds is warranted.
Subscribe to updates from Inotiv
Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.
